Recurring Revenue Growth
Recurring revenue increased 23% year-to-date compared to the same period in 2023, with treatment revenue growing 14% and service revenue 22% in Q3.
Gross Margin Expansion
Non-GAAP gross margin expanded by nearly 11 percentage points from Q3 of last year, with product gross margin at 44.9% and service and other gross margin at 15.8%.
Commercial Transformation Progress
The commercial team has been retooled, with new sales processes implemented, leading to early signs of positive impact in Q3.
Home End Market Success
Tablo home program locations have increased 40% over the last 18 months, with a 90-day retention rate above 90% compared to the industry average of 65%.
Strong Cash Position and Expense Management
Ended Q3 with $179 million in cash and equivalents, and operating expenses decreased 37% year-over-year.